BNTX vs. TMO: BioNTech vs. Thermo Fisher Scientific Stock Comparison

Company Profile

BioNTech (BNTX) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Thermo Fisher Scientific (TMO) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Thermo Fisher Scientific (TMO) reports 13.38%, ranking against industry peers normally.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Thermo Fisher Scientific (TMO) reports 14.94%, ranking against industry peers normally.

Both BioNTech (BNTX) at 30.28% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioNTech (BNTX) at 4.32% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TMO.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Thermo Fisher Scientific (TMO) at 0.75 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

BioNTech (BNTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

BioNTech (BNTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Thermo Fisher Scientific (TMO) trades at 36.64 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

On P/S ratio, both BioNTech (BNTX) at 8.96 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Thermo Fisher Scientific (TMO) at 4.70 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics